Clinical trials: Non Erosive Reflux Disease
Non-erosive Reflux Disease
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease
The purpose of this study is to demonstrate the superiority of efficacy of CJ-12420, once daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4
- Trial name
- NCT02556021
- Testing
- CJ-12420 50mg, CJ-12420 100mg
- Where
- South Korea
- Volunteers
- 324 people
- Sponsor
- HK inno.N Corporation
Non-Erosive Gastroesophageal Reflux Disease
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease
The purpose of this study is to demonstrate the superiority of efficacy of DWP14012, once daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4.
- Trial name
- NCT03811080
- Testing
- DWP14012 A mg, DWP14012 B mg
- Where
- South Korea
- Volunteers
- 327 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Non-erosive Reflux Disease
Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients
Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients
- Trial name
- NCT03967886
- Testing
- YYD601 20mg, Nexium 20mg
- Where
- South Korea
- Volunteers
- 170 people
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Gastric Ulcer (GU), Duodenal Ulcer (DU)
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in Japanese paediatric patients aged 1 to 14 years old…
- Conditions
- Gastric Ulcer (GU), Duodenal Ulcer (DU), Anastomotic Ulcer (AU), Non-erosive Reflux Esophagitis Disease (NERD)
- Trial name
- NCT02153398
- Testing
- D961H sachet 10 mg, D961H capsule 10mg, D961H capsule 20 mg
- Where
- 15 sites in Japan
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Non Erosive Reflux Disease
S-pantoprazole 10mg Phase III Clinical Study
This clinical study hypothesized that S-pantoprazole 10mg would be effective to treat Non erosive Reflux Disease than placebo.
- Trial name
- NCT02274961
- Testing
- S-pantoprazole 10mg
- Where
- 10 sites in South Korea
- Volunteers
- 174 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
The primary objectives of this study are to assess the efficacy of vonoprazan (10 mg and 20 mg once daily [QD]) compared to placebo (QD) in relief of heartburn over 4 weeks in participants with NERD.
- Trial name
- NCT05195528
- Testing
- Vonoprazan
- Where
- 108 sites in United States
- Volunteers
- 776 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Gastroesophageal Reflux
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the…
- Trial name
- NCT00163306
- Testing
- Pantoprazole
- Where
- 79 sites in Austria, Germany and 2 more
- Volunteers
- 1,200 people
- Sponsor
- Takeda
Non-erosive Gastroesophageal Reflux Disease
A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810…
- Trial name
- NCT00165672
- Testing
- RABEPRAZOLE SODIUM
- Where
- 13 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Eisai Inc.
Non-erosive Reflux Disease
Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)
Randomized, double-blind, active-controlled, multi-center phase 2 clinical trial to investigate the safety, tolerability and efficacy of YH1885L in patients with non-erosive reflux disease(NERD)
- Trial name
- NCT01750437
- Testing
- YH1885L(Revaprazan), Esomeprazole 20mg
- Where
- 10 sites in South Korea
- Volunteers
- 149 people
- Sponsor
- Yuhan Corporation
Non-erosive Reflux Disease(NERD)
Clinical Trial to Evaluate the Efficacy and Safety of EsoDuo Tab. 20/800mg
To Evaluate the Efficacy and Safety of EsoDuo Tab. 20/800mg
- Trial name
- NCT03928470
- Testing
- EsoDuo Tab. 20/800mg
- Where
- 38 sites in South Korea
- Volunteers
- 379 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Non-erosive Reflux Disease, Erosive Esophagitis
A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease
The objective of this study is to evaluate the safety of up to 12 months (52 weeks) of once daily oral administration of BLI5100 in patients with non-erosive reflux disease (NERD) or healed erosive esophagitis (EE).
- Trial name
- NCT05890001
- Testing
- BLI5100
- Where
- 60 sites in United States
- Volunteers
- 400 people
- Sponsor
- Braintree Laboratories
Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)
Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis
This study aims to evaluate the Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects with Healed Erosive Esophagitis
- Trial name
- NCT07732075
- Testing
- JP-1366 10 mg, Lansoprazole 15mg
- Volunteers
- 384 people
- Sponsor
- Onconic Therapeutics Inc.
GERD
Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease
The aim of this trial is to evaluate the complete remission of erosive gastroesophageal reflux disease with pantoprazole magnesium 40 mg once daily versus esomeprazole 40 mg once daily during four-week treatment with an extension…
- Trial name
- PAMES 0109 (NCT01132638)
- Testing
- Magnesium Pantoprazole, Magnesium Esomeprazole
- Where
- 9 sites in Brazil
- Volunteers
- 713 people
- Sponsor
- Takeda
Sleep Disorders, Non-Erosive Reflux Disease
Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders
The aim of the study was to evaluate the effect of pantoprazole on sleep disorders in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease).
- Conditions
- Sleep Disorders, Non-Erosive Reflux Disease, Gastroesophageal Reflux Disease
- Trial name
- PANDA (NCT00830115)
- Testing
- Pantoprazole
- Where
- 201 sites in Germany
- Volunteers
- 1,045 people
- Sponsor
- Nycomed
Non-erosive Gastroesophageal Reflux Disease
A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux disease in a multicenter, randomized, double-blind…
- Trial name
- NCT00165646
- Testing
- E3810
- Where
- 35 sites in Japan
- Volunteers
- 288 people
- Sponsor
- Eisai Co., Ltd.
Non-erosive Reflux Disease
Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
The purpose of this study is to study safety and efficacy of omeprazole standard treatment in a Japanese non-erosive reflux disease population.
- Trial name
- NCT00259077
- Testing
- Omeprazole
- Where
- 26 sites in Japan
- Volunteers
- 270 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
Gastroesophageal reflux disease (GERD) considered to be associated with mucosal damages in the esophagus and heartburn, which may sometimes interfere with daily activities due likely to reflux of acid gastric contents.
- Trial name
- NCT00141960
- Testing
- Famotidine
- Where
- 7 sites in Japan
- Volunteers
- 480 people
- Sponsor
- Astellas Pharma Inc
Gastroesophageal Reflux Disease
Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn
The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn…
- Trial name
- NCT00251745
- Testing
- Dexlansoprazole MR
- Where
- 95 sites in United States
- Volunteers
- 908 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
The purpose of this study was to assess the safety and effectiveness of once daily oral administration of dexlansoprazole delayed-release capsules in adolescent participants with symptomatic non-erosive gastroesophageal reflux…
- Trial name
- NCT01642602
- Testing
- Dexlansoprazole
- Where
- 64 sites in United States, Belgium and 6 more
- Volunteers
- 104 people
- Sponsor
- Takeda
Erosive Esophagitis, Heartburn
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
The main objective of the study is to compare the maternal, fetal, and infant outcomes of pregnant women who are exposed to vonoprazan during pregnancy with outcomes of an internal comparison cohort of pregnant women who are…
- Conditions
- Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Helicobacter Pylori Infection
- Trial name
- NCT06660342
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 728 people
- Sponsor
- Phathom Pharmaceuticals, Inc.